2013 has been an important year in retina therapy, with increased information released on nutritional supplements for AMD patients, widened indications for anti-VEGFs and the approval of treatment for symptomatic vitreomacular adhesion.
Study: caffeine does not impact retinal vessel density, despite effects on blood pressure
Caffeine has been shown to temporarily increase intraocular pressure and reduce blood flow in critical ocular regions
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
Ocuphire Pharma and Opus Genetics announce merger
The company also announced it will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy.
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Alzheimer disease retinopathy and brain-to-eye β-amyloid transport
The research findings highlighted a new therapeutic avenue in ocular and neurodegenerative disease
Study: Oral caffeine intake increases inner electro-retinal activity in young adults
Investigators studied global-flash multifocal electroretinogram responses